# Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

> **NCT03270059** · PHASE2 · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 150 (estimated)

## Conditions studied

- Central Nervous System Neoplasm
- Cranial Nerve Disorder
- Metastatic Malignant Neoplasm in the Brain

## Interventions

- **DRUG:** Ferumoxytol
- **DRUG:** Gadolinium
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03270059
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-10-06
- **Primary completion:** 2027-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270059, "Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03270059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*